Denali Therapeutics Biogen Initiate Phase 2B Study Of Lrrk2 Inhibitor In Parkinsons Disease
Denali Therapeutics Inc., A Biopharmaceutical Company, And Biogen Inc. Announced That Dosing Has Commenced In The Global Phase 2B Luma Study To Evaluate The Efficacy And Safety Of Biib122 (Dnl151), As Compared To Placebo In Approximately 640 Participants With Early-Stage Parkinson
Let’s apply Data-Driven Pricing to Your APIs
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions!
Learn More!